Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO...

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Relapsed/refractory large B cell lymphoma (R/R LBCL) presents a significant clinical challenge.
• Autologous stem cell transplant (ASCT) is a key therapeutic strategy for R/R LBCL.
• Efficacy of ASCT following rituximab-containing frontline therapy requires further evaluation.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of ASCT in a large cohort of R/R LBCL patients.
• To identify prognostic factors influencing outcomes after ASCT in R/R LBCL.
• To assess the impact of frontline therapy on ASCT outcomes.

Main Methods:

• Retrospective multicenter study of 791 R/R LBCL patients undergoing ASCT (2010-2021).
• Patients received rituximab and anthracycline-based frontline therapy.
• Analysis of progression-free survival (PFS), overall survival (OS), and non-relapse mortality (NRM).

Main Results:

• At a median follow-up of 74 months, 65% of patients were alive and 84% were disease-free.
• Six-year PFS and OS were 51% and 63%, respectively.
• Independent predictors of worse PFS and OS included age >60 years, ASCT as ≥3rd line, and partial response/stable disease pre-ASCT.

Conclusions:

• ASCT demonstrates significant long-term efficacy in R/R LBCL patients treated with modern frontline therapy.
• Achieving complete response prior to ASCT is crucial for optimal outcomes.
• ASCT remains a potentially curative option for selected R/R LBCL patients.